Dr. Reddys Laboratories is currently trading at Rs. 2362.15, up by 29.10 points or 1.25% from its previous closing of Rs. 2333.05 on the BSE.
The scrip opened at Rs. 2320.10 and has touched a high and low of Rs. 2371.60 and Rs. 2320.10 respectively. So far 26388 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3203.95 on 06-Jan-2017 and a 52 week low of Rs. 1901.65 on 11-Aug-2017.
Last one week high and low of the scrip stood at Rs. 2425.00 and Rs. 2320.10 respectively. The current market cap of the company is Rs. 38995.95 crore.
The promoters holding in the company stood at 26.77%, while Institutions and Non-Institutions held 43.15% and 15.25% respectively.
Dr. Reddy’s Laboratories has launched Melphalan Hydrochloride for Injection, a therapeutic equivalent generic version of Alkeran (melphalan hydrochloride) for Injection in the United States market approved by the U.S. Food and Drug Administration (USFDA). The Alkeran brand and generic had U.S. sales of around $107 million MAT for the most recent twelve months ending in October-2017 according to IMS Health.
Dr. Reddy's Melphalan Hydrochloride for Injection is available in a carton containing one single-dose clear glass vial of freeze-dried melphalan hydrochloride equivalent to 50 mg melphalan and one 10 mL clear glass vial of sterile diluent.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |